Recursion Pharmaceuticals, Inc. (RXRX) Financials

RXRX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.3 billion 314.8 million
Dec. 31, 2025 1.5 billion 343.3 million
Sept. 30, 2025 1.4 billion 352.6 million
June 30, 2025 1.3 billion 383.2 million

RXRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -81.4 million 22.2 million
Dec. 31, 2025 -47.3 million 23.8 million
Sept. 30, 2025 -117.6 million 25.2 million
June 30, 2025 -79.6 million 26.2 million

RXRX Net Income

No data available :(

RXRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 654.5 million 50.0 million 55.9 million
Dec. 31, 2025 743.3 million 56.2 million 59.3 million
Sept. 30, 2025 659.8 million 61.9 million 61.6 million
June 30, 2025 528.2 million 14.2 million 65.1 million

RXRX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 529.3 million
Dec. 31, 2025 526.7 million
Sept. 30, 2025 447.0 million
June 30, 2025 417.4 million

RXRX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 258000 87.9 million 34.6 million -
Dec. 31, 2025 1.2 million 83.3 million 33.7 million -
Sept. 30, 2025 243000 121.1 million 41.6 million -
June 30, 2025 3.2 million 128.6 million 46.7 million -

RXRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 6.5 million 12.5 million
Dec. 31, 2025 35.5 million 26.9 million
Sept. 30, 2025 5.2 million 29.6 million
June 30, 2025 19.1 million 20.2 million

RXRX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

RXRX

Price: $3.29

52 week price:
2.77
7.18

Earnings Per Share: -1.16 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 732400

Market Capitalization: 1.5 billion

Links: